Introduction
NSCLC, SCLC, non-small-cell lung cancer, lung cancer, small-cell lung cancer
LUNG CANCER, SOLID TUMORS, SCLC, NSCLC
Approximately 15% of lung cancer cases are small-cell lung cancer (SCLC), which has a poor prognosis (Since the advent of immune checkpoint inhibitors (ICIs), treatment for many solid tumors has been subverted. Furthermore, SCLC has a high mutation rate, making ICIs an attractive therapeutic option (Camrelizumab is a humanized high-affinity IgG4-kappa anti-PD-1 monoclonal antibody, which has been approved in combination with chemotherapy (carboplatin plus paclitaxel or pemetrexed) for the first-line treatment of advanced non-small-cell lung cancer (NSCLC) (